Diagnosis and therapy of pemphigus – consensus of Polish Dermatological Society

Pemphigus is an acantholytic bullous disease with a potentially fatal course. The laboratory diagnosis of pemphigus is based on direct immunofluorescence showing the presence of the in vivo bound IgG in intercellular spaces of the epidermis in skin biopsy. For determining the clinical subtypes of pemphigus serum immunological studies allowing characterization of the target antigen(s) are obligatory. Treatment of pemphigus with prednisone at an initial dose of 1–1.5 mg/kg in combination with azathioprine is currently recommended by most dermatologists as well as by the European Expert Group as the therapy of choice in typical SłoWA KLuCzoWE: pęcherzyca, bezpośrednie badanie immunopatologiczne, ELISA, wytyczne, leczenie. KEy WoRDS: pemphigus, direct immunofluorescence, ELISA, guidelines, treatment. ADRES Do KoRESPoNDENCJI: prof. dr hab. n. med. Cezary Kowalewski Klinika Dermatologii i Immunodermatologii Warszawski Uniwersytet Medyczny ul. Koszykowa 82A 02-008 Warszawa

[1]  S. Jabłońska,et al.  Pemphigus herpetiformis: from first description until now. , 2014, Journal of the American Academy of Dermatology.

[2]  F. Davatchi,et al.  Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  D. Rigopoulos,et al.  Evaluation of mycophenolate mofetil as a steroid‐sparing agent in pemphigus: a randomized, prospective study , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  D. Zillikens,et al.  Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients , 2012, The British journal of dermatology.

[5]  M. Hertl,et al.  Autoimmune bullous skin diseases. Part 2: diagnosis and therapy , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[6]  M. Hertl,et al.  Autoimmune bullous skin diseases. Part 1: Clinical manifestations , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[7]  Pascal Joly,et al.  Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). , 2011, Clinics in dermatology.

[8]  D. Murrell,et al.  A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. , 2011, Journal of the American Academy of Dermatology.

[9]  C. Bédane,et al.  [Pemphigus. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. , 2011, Annales de dermatologie et de venereologie.

[10]  A. Siadat,et al.  Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. , 2010, Journal of drugs in dermatology : JDD.

[11]  L. Medenica,et al.  Dexamethasone-Cyclophosphamide Pulse Therapy in Pemphigus , 2010, American journal of clinical dermatology.

[12]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[13]  D. Murrell,et al.  Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.

[14]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[15]  D. Zillikens,et al.  Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases § , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  D. Fivenson,et al.  Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. , 2008, Archives of dermatology.

[17]  C. Chams‐Davatchi,et al.  Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. , 2007, Journal of the American Academy of Dermatology.

[18]  D. Zillikens,et al.  Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[19]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[20]  C. Sitaru,et al.  Immunopathology and molecular diagnosis of autoimmune bullous diseases , 2007, Journal of cellular and molecular medicine.

[21]  M. Dmochowski,et al.  Zmiany w krtani w pęcherzycy zwykłej z dominacją zmian na błonach śluzowych , 2007 .

[22]  S. Cohen,et al.  Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus , 2006, International journal of dermatology.

[23]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[24]  H. Gollnick,et al.  A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. , 2006, Archives of dermatology.

[25]  R. Brodsky,et al.  Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. , 2003, Journal of the American Academy of Dermatology.

[26]  J. Mclelland,et al.  Thiopurine methyltransferase levels should be measured before commening patients on azathioprine , 1997, The British journal of dermatology.

[27]  Masayuki Amagai,et al.  Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion , 1991, Cell.

[28]  E. Beutner,et al.  HERPETIFORM PEMPHIGUS, A VARIABLE PATTERN OF PEMPHIGUS , 1975, International journal of dermatology.